Therapy Detail

Therapy Name Telisotuzumab vedotin
Synonyms
Therapy Description

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET expressing tumor cells, resulting in cell death (PMID: 27573171).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Telisotuzumab vedotin ABBV-399|Teliso-V MET Antibody 13 Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET expressing tumor cells, resulting in cell death (PMID: 27573171).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET over exp lung adenocarcinoma predicted - sensitive Telisotuzumab vedotin Preclinical - Pdx Actionable In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171). 27573171
MET positive lung non-small cell carcinoma sensitive Telisotuzumab vedotin Phase I Actionable In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)). detail...
MET over exp lung non-small cell carcinoma sensitive Telisotuzumab vedotin Phase I Actionable In a Phase I trial, Telisotuzumab vedotin (ABBV-399) was well-tolerated and resulted in a disease control rate of 56% (9/16) in patients with MET-overexpressing non-small cell lung cancer, with partial response in 19% (3/16) and stable disease in 38% (6/16), and resulted in reduction in target lesions in 44% (7/16) of patients (PMID: 30285518; NCT02099058). detail... 30285518
MET over exp lung non-small cell carcinoma sensitive Telisotuzumab vedotin Preclinical - Cell culture Actionable In a preclinical study, Telisotuzumab vedotin (ABBV-399) inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171). 27573171
MET over exp lung papillary adenocarcinoma sensitive Telisotuzumab vedotin Preclinical - Cell culture Actionable In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171). 27573171
MET amp stomach cancer sensitive Telisotuzumab vedotin Preclinical - Cell line xenograft Actionable In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171). 27573171

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer Recruiting
NCT02099058 Phase I Carboplatin + Telisotuzumab vedotin Erlotinib + Telisotuzumab vedotin Telisotuzumab vedotin Bevacizumab + Telisotuzumab vedotin Cetuximab + Telisotuzumab vedotin A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors Recruiting
NCT03574753 Phase II Telisotuzumab vedotin Lung-MAP S1400K: c-MET Positive Active, not recruiting


Additional content available in CKB BOOST